ESR1 and breast cancer: Because HER2-positivity in HR+ breast cancer is associated with ET resistance, potentially due to the crosstalk mechanism(s), including attenuation of ER and PR expression8, hormone sensitivity may theoretically be restored through HER2 blockade111.